Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
An MC4R (melanocortin 4 receptor) agonist FDA-approved for rare genetic obesity disorders including POMC, PCSK1, and LEPR deficiency. Represents a precision medicine approach to obesity treatment.
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.
Activates the MC4R pathway in the hypothalamus, restoring satiety signaling that is disrupted in specific genetic obesity conditions. Unlike GLP-1 agonists, it targets the melanocortin pathway directly.
Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.
- Rare genetic obesity (POMC deficiency)
- PCSK1 deficiency obesity
- LEPR deficiency obesity
- Weight management
- Type 2 diabetes treatment
- Blood sugar regulation
- Cardiovascular risk reduction
- Skin hyperpigmentation (common)
- Injection site reactions
- Depression and suicidal ideation (boxed warning)
- Spontaneous penile erections
- Very narrow approved indication
- Nausea and vomiting (common, usually transient)
- Pancreatitis (rare but serious)
- Gallbladder issues
- Potential thyroid tumor risk (animal studies)
- Muscle mass loss alongside fat loss
- GI side effects (diarrhea, constipation)
FDA-approved as Imcivree (2020) for chronic weight management in patients 6+ years with obesity due to POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. Not approved for general obesity.
FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.
- Setmelanotide for POMC deficiency obesity
2020 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.